Protective autophagy or autophagic death: effects of BEZ235 on chronic myelogenous leukemia

References

• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172–183.15719031
   PubMed Web of Science ®Google Scholar
• Holyoake TL. Recent advances in the molecular and cellular biology of chronic myelogenous leukaemia: lessons to be learned from the laboratory. Br J Haematol. 2001;113(1):11–23.11328274
   PubMed Web of Science ®Google Scholar
• Vakil E, Tefferi A. BCR-ABL1–negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 2011;11(Suppl 1):S37–S45.22035746
   PubMedGoogle Scholar
• Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myelogenous leukemia. Blood. 2009;113(8):1619–1630.18827185
   PubMed Web of Science ®Google Scholar
• Apperley JF. Chronic myelogenous leukaemia. Lancet. 2015;385(9976):1447–1459.25484026
   PubMed Web of Science ®Google Scholar
• Apperley JF, Part I. mechanisms of resistance to imatinib in chronic myelogenous leukaemia. Lancet Oncol. 2007;8(11):1018–1029.17976612
   PubMed Web of Science ®Google Scholar
• Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myelogenous leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood. 2008;111(4):2329–2338.18056843
   PubMed Web of Science ®Google Scholar
• Xu XH, Gan YC, Xu GB, et al. Tetrandrine citrate eliminates imatinib-resistant chronic myelogenous leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/beta-catenin axis. J Zhejiang Univ Sci B. 2012;13(11):867–874.23125079
   PubMed Web of Science ®Google Scholar
• Ahmed W, Van Etten RA. Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep. 2013;8(1):71–80.23307472
   PubMed Web of Science ®Google Scholar
• Mak DH, Schober WD, Chen W, et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009;8(9):2509–2516.19723894
   PubMed Web of Science ®Google Scholar
• Kuger S, Corek E, Polat B, et al. Novel PI3K and mTOR inhibitor BEZ235 radiosensitizes breast cancer cell lines under normoxic and hypoxic conditions. Breast Cancer (Auckl). 2014;8:39–49.24678241
   PubMedGoogle Scholar
• Wang H, Zhang L, Yang X, et al. PUMA mediates the combinational therapy of 5-FU and BEZ235 in colon cancer. Oncotarget. 2015;6(16):14385–14398.25965911
   PubMedGoogle Scholar
• Hall CP, Reynolds CP, Kang MH. Modulation of glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia by increasing BIM expression with the PI3K/mTOR inhibitor BEZ235. Clin Cancer Res. 2016;22(3):621–632.26080839
   PubMed Web of Science ®Google Scholar
• Chandrasekhar C, Kumar PS, Sarma PVGK. Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. Sci Rep. 2019;9(1):2412.30787317
   PubMedGoogle Scholar
• Kang KH, Kim SH, Choi SY, et al. Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia. Leuk Res. 2019;76:87–93.30503643
   PubMed Web of Science ®Google Scholar
• Wu J, Meng F, Lu H, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood. 2008;111(7):3821–3829.18235045
   PubMed Web of Science ®Google Scholar
• Elias MH, Baba AA, Husin A, et al. HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients. Biomed Res Int. 2013;1:129715.
   Google Scholar
• Uziel O, Fenig E, Nordenberg J, et al. Imatinib mesylate (gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 2005;92(10):1881.15870711
   PubMed Web of Science ®Google Scholar
• Hekmatshoar Y, Ozkan T, Altinok BG, et al. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms. Cell Mol Biol (noisy-le-grand). 2018;64(6):23–30.
   PubMed Web of Science ®Google Scholar
• Han SH, Korm S, Han YG, et al. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia. Autophagy. 2019;1–15.
   Google Scholar
• Mitchell R, Hopcroft LE, Baquero P, et al. Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition. JNCI. 2017;110(5):467–478.
   Google Scholar
• Bedewy AM, Elmaghraby SM, Kandil NS. ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy. Blood Res. 2019;54(1):57–62.30956965
   PubMed Web of Science ®Google Scholar
• Noel BM, Ouellette SB, Marholz L, et al. Multi-omic profiling of TKI resistant K562 cells suggests metabolic reprogramming to promote cell survival. J Proteome Res. 2019;18(4):1842–1856.30730747
   PubMed Web of Science ®Google Scholar
• Chandran RK, Geetha N, Sakthivel KM, et al. Differential gene expression changes and their implication on the disease progression in patients with chronic myeloid leukemia. Blood Cells Mol Dis. 2019;77:51–60.30959263
   PubMed Web of Science ®Google Scholar
• Nievergall E, Ramshaw HS, Yong AS, et al. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014;123(8):1218–1228.24363400
   PubMed Web of Science ®Google Scholar
• Blank U, Karlsson S. TGF-β signaling in the control of hematopoietic stem cells. Blood. 2015;125(23):3542–3550.25833962
   PubMed Web of Science ®Google Scholar
• Madapura HS, Nagy N, Ujvari D, et al. Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells. Oncogene. 2017;36(32):4619.28368400
   PubMed Web of Science ®Google Scholar
• Eldeeb M, Fahlman R. The-N-end rule: the beginning determines the end. Protein Pept Lett. 2016;23(4):343–348.26743630
   PubMed Web of Science ®Google Scholar
• Piatkov KI, Brower CS, Varshavsky A. The N-end rule pathway counteracts cell death by destroying proapoptotic protein fragments. Proc Natl Acad Sci. 2012;109(27):E1839–E1847.22670058
   PubMed Web of Science ®Google Scholar
• Eldeeb M, Fahlman R, Esmaili M, et al. Regulating apoptosis by degradation: the N-end rule-mediated regulation of apoptotic proteolytic fragments in mammalian cells. Int J Mol Sci. 2018;19(11):3414.
   PubMed Web of Science ®Google Scholar
• Wu J, Meng F, Kong LY, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. JNCI. 2008;100(13):926–939.18577747
   PubMedGoogle Scholar
• Eldeeb MA, Fahlman RP. The anti-apoptotic form of tyrosine kinase Lyn that is generated by proteolysis is degraded by the N-end rule pathway. Oncotarget. 2014;5(9):2714.24798867
   PubMedGoogle Scholar
• El Eit R, Itani AR, Nassar F, et al. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Cancer. 2019; 125:2818–2828.
   PubMedGoogle Scholar
• Jia X, Zheng Y, Guo Y, et al. Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways. Mol Genet Genomic Med. 2019;7:e613.30891950
   PubMed Web of Science ®Google Scholar
• Rothe K, Porter V, Jiang X. Current outlook on autophagy in human leukemia: foe in cancer stem cells and drug resistance, friend in new therapeutic interventions. Int J Mol Sci. 2019;20(3):461.
   PubMed Web of Science ®Google Scholar
• Arken N. Schizandrol A reverses multidrug resistance in resistant chronic myeloid leukemia cells K562/A02. Cell Mol Biol (noisy-le-grand). 2019;65(1):78–83.30782299
   PubMed Web of Science ®Google Scholar
• KC R, Thapa B, Ubeda A, Jiang X, Uludağ H. BCR-Abl silencing by short interfering RNA: a potent approach to sensitize chronic myeloid leukemia cells to tyrosine kinase inhibitor therapy. Stem Cells Dev. 2019;28(11):734–744.
   PubMed Web of Science ®Google Scholar
• Jiang X, Cheng Y, Hu C, et al. MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5. Leuk Lymphoma. 2019;60(7):1709–1720.
   Web of Science ®Google Scholar
• Craddock CF. We do still transplant CML, don’t we? Hematology Am Soc Hematol Educ Program. 2018;2018(1):177–184.30504307
   PubMedGoogle Scholar
• Xin P, Li C, Zhu X, et al. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Drug Des Devel Ther. 2017;11:1115–1126.
   PubMed Web of Science ®Google Scholar
• Wu YT, Tan HL, Huang Q, et al. Activation of the PI3K-Akt-mTOR signaling pathway promotes necrotic cell death via suppression of autophagy. Autophagy. 2009;5(6):824–834.19556857
   PubMed Web of Science ®Google Scholar
• Qin L, Wang Z, Tao L, et al. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy. 2010;6(2):239–247.20104019
   PubMed Web of Science ®Google Scholar
• Tanida I, Minematsu-Ikeguchi N, Ueno T, et al. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy. 2005;1(2):84–91.16874052
   PubMed Web of Science ®Google Scholar
• Ju JS, Varadhachary AS, Miller SE, et al. Quantitation of “autophagic flux” in mature skeletal muscle. Autophagy. 2010;6(7):929–935.20657169
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8(4):445–544.22966490
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1–222.26799652
   PubMed Web of Science ®Google Scholar
• Liu TJ, Koul D, LaFortune T, et al. BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther. 2009;8(8):2204–2210.19671762
   PubMed Web of Science ®Google Scholar
• Clarke PGH, Puyal J. Autophagic cell death exists. Autophagy. 2012;8(6):867–869.22652592
   PubMed Web of Science ®Google Scholar
• Cerniglia GJ, Karar J, Tyagi S, et al. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235. Mol Pharmacol. 2012;82(6):1230–1240.22989521
   PubMed Web of Science ®Google Scholar
• Shen SS, Kepp O, Kroemer G. The end of autophagic cell death? Autophagy. 2012;8(1):1–3.22082964
   PubMed Web of Science ®Google Scholar
• Ji YH, Di WY, Yang QH, et al. Inhibition of autophagy increases proliferation inhibition and apoptosis induced by the PI3K/mTOR inhibitor BEZ235 in breast cancer cells. Clin Lab. 2015;61(8):1043–1051.26427150
   PubMed Web of Science ®Google Scholar
• Yu Z, Xie G, Zhou G, et al. BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Cancer Lett. 2015;367(1):58–68.26188279
   PubMed Web of Science ®Google Scholar
• Schrauwen S, Depreeuw J, Coenegrachts L, et al. Dual blockade of PI3K/AKT/mTOR (BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas BEZ235 reduces tumor growth in the corresponding xenograft models. Gynecol Oncol. 2015;138(1):165–173.25933683
   PubMed Web of Science ®Google Scholar
• Ribback S, Cigliano A, Kroeger N, et al. PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. Oncotarget. 2015;6(15):13036–13048.25948777
   PubMedGoogle Scholar
• Fraveto A, Cardinale V, Bragazzi MC, et al. Sensitivity of human intrahepatic cholangiocarcinoma subtypes to chemotherapeutics and molecular targeted agents: a study on primary cell cultures. PLoS One. 2015;10(11):e0142124.26571380
   PubMed Web of Science ®Google Scholar